Evidence map›Paper›PMID 27001839›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2016

CRLX101 nanoparticles localize in human tumors and not in adjacent, nonneoplastic tissue after intravenous dosing.

Andrew J Clark, Devin T Wiley, Jonathan E Zuckerman, Paul Webster, Joseph Chao, James Lin, Yun Yen, Mark E Davis

Registry-linked trialOpen access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02648711 (Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies), which is not on this map. Cited by 61 papers.

0numbers the graph read from it
0cells of the map it votes in
61citing papers in PubMed
22.2field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02648711 phase1terminatednot on this map

Evaluation of an Alternative Schedule for CRLX101 Alone in Combination With Bevacizumab and in Combination With mFOLFOX6 in Subjects With Advanced Solid Tumor Malignancies

TypeinterventionalSponsorNewLink Genetics CorporationRan2015 to 2018Enrolled41ConditionsSolid TumorsArmsCRLX101, Bevacizumab, mFOLFOX6
3 · Its place in the literature

Who cites it

61 citing papers in PubMed, 166 citations in OpenAlex.

  1. Trial
  2. Trial
  3. Trial
  4. Trial
  5. Trial
  6. Review
  7. Review
  8. Review
  9. Review
  10. Review
  11. Review
  12. Review
  13. Review
  14. Review
  15. Review
  16. Review
  17. Article
  18. Review
  19. Article
  20. Targeting hypoxia in solid and haematological malignancies.Journal of experimental & clinical cancer research : CR · 2022
    Review

1 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 4 institutions in 2 countries.

Andrew J ClarkDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125;
Devin T WileyDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125;
Jonathan E ZuckermanDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125; Department of Pathology and Laboratory Medicine, University of California, Los Angeles, CA 90095;
Paul WebsterOak Crest Institute of Science, Pasadena, CA 91107;
Joseph ChaoDepartment of Medical Oncology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010.
James LinDivision of Gastroenterology, City of Hope Comprehensive Cancer Center, Duarte, CA 91010;
Yun YenGraduate Institute for Cancer Biology and Drug Discovery, Taipei Medical University, Taipei 11031, Taiwan mdavis@cheme.caltech.edu yyen@tmu.edu.tw.
Mark E DavisDivision of Chemistry and Chemical Engineering, California Institute of Technology, Pasadena, CA 91125; mdavis@cheme.caltech.edu yyen@tmu.edu.tw.
California Institute of Technology · USCity of Hope · USOak Crest Institute of Science · USTaipei Medical University · TW

Funding

Oncology Research Career Development ProgramK12CA001727 · NCI · CITY OF HOPE NATIONAL MEDICAL CENTER · PI MORTIMER, JOANNE E. · 1992 to 2024
$14.6M
UCLA Institute for Molecular Medicine (IMED) CoreU54CA151819 · NCI · CALIFORNIA INSTITUTE OF TECHNOLOGY · PI HOOD, LEROY E · 2010 to 2014
$12.1M
NCI NIH HHS K12 CA001727NCI NIH HHS L30 CA179788NCI NIH HHS U54 CA151819
6 · The paper itself

Abstract

Nanoparticle-based therapeutics are being used to treat patients with solid tumors. Whereas nanoparticles have been shown to preferentially accumulate in solid tumors of animal models, there is little evidence to prove that intact nanoparticles localize to solid tumors of humans when systemically administered. Here, tumor and adjacent, nonneoplastic tissue biopsies are obtained through endoscopic capture from patients with gastric, gastroesophageal, or esophageal cancer who are administered the nanoparticle CRLX101. Both the pre- and postdosing tissue samples adjacent to tumors show no definitive evidence of either the nanoparticle or its drug payload (camptothecin, CPT) contained within the nanoparticle. Similar results are obtained from the predosing tumor samples. However, in nine of nine patients that were evaluated, CPT is detected in the tumor tissue collected 24-48 h after CRLX101 administration. For five of these patients, evidence of the intact deposition of CRLX101 nanoparticles in the tumor tissue is obtained. Indications of CPT pharmacodynamics from tumor biomarkers such as carbonic anhydrase IX and topoisomerase I by immunohistochemistry show clear evidence of biological activity from the delivered CPT in the posttreatment tumors.

Indexed as

AnimalsAntineoplastic Agents, PhytogenicBiomarkers, TumorCamptothecinCarbonic Anhydrase IXCell Line, TumorCyclodextrinsDNA Topoisomerases, Type IEndoscopyEsophageal NeoplasmsHumansMiceNanoparticlesStomach NeoplasmsXenograft Model Antitumor AssaysAntineoplastic Agents, PhytogenicBiomarkers, TumorCamptothecinCarbonic Anhydrase IXCyclodextrinsDNA Topoisomerases, Type IIT-101clinical trialgastric cancernanomedicinenanoparticlestumor targeting

Identifiers

PMID27001839
PMCPMC4833237
OpenAlexW2306899626

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.